Probiotic compositions suitable for intravaginal administration to a non-human animal comprising one or more strains of bacteria native to the vagina of the species of animal and a non-aqueous base, probiotic products, kits, and systems comprising the probiotic compositions, and methods of using the probiotic compositions, products, kits, and systems.

Probiotic compositions suitable for intravaginal administration to a non-human animal comprising one or more strains of bacteria native to the vagina of the species of animal and a non-aqueous base, probiotic products, kits, and systems comprising the probiotic compositions, and methods of using the probiotic compositions, products, kits, and systems.

A composition including endometrial, especially mesenchymal stem cells (EnMSC), for use in a method for the treatment of poor ovarian response and a method for banking endometrial, especially mesenchymal, stem cells.

A composition including endometrial, especially mesenchymal stem cells (EnMSC), for use in a method for the treatment of poor ovarian response and a method for banking endometrial, especially mesenchymal, stem cells.

Provided is a novel compound that has an excellent β-lactamase inhibitory effect. More specifically, provided is a compound represented by formula (1a), (1b) or (11) having an excellent β-lactamase inhibitory effect or a pharmaceutically acceptable salt thereof. By using this compound either in combination with a β-lactam drug or alone, a useful preventive or therapeutic agent for bacterial infections is provided. Also provided are useful preventive or therapeutic agents for treating various diseases with the combined use of the aforesaid compound and β-lactam drugs.

An agent capable of promoting proliferation and differentiation of granulosa cells is disclosed which comprises a growth and differentiation factor-9 (GDF9) protein comprising a modified GDF9 polypeptide monomer which includes at least one amino acid substitution that enhances binding to and/or activation of activin-like kinase 4 and/or 5 receptor (ALK4/5). The agent is preferably provided in a mature dimeric form (eg comprising two monomers of the same modified GDF9 polypeptide monomer) and/or in a pro/mature complex form. The agent may be suitable for, inter alia, promoting oocyte maturation in vitro for use in assisted reproductive technologies.

A testicular function-improving agent which contains microparticles derived from a culture supernatant of dental pulp-derived stem cells, adipose-derived stem cells or immortalized stem cells thereof and in which the improvement of a testicular function is improvement of the ability of a testis itself to form sperm, improvement of the function of sperm themselves obtained from a testis, improvement of the function of sperm obtained from a testis of acting on a female, rejuvenation of any of the functions that has aged with aging or activation of sperm through addition to semen taken out of the body of an animal can significantly improve a testicular function of an animal.

A testicular function-improving agent which contains microparticles derived from a culture supernatant of dental pulp-derived stem cells, adipose-derived stem cells or immortalized stem cells thereof and in which the improvement of a testicular function is improvement of the ability of a testis itself to form sperm, improvement of the function of sperm themselves obtained from a testis, improvement of the function of sperm obtained from a testis of acting on a female, rejuvenation of any of the functions that has aged with aging or activation of sperm through addition to semen taken out of the body of an animal can significantly improve a testicular function of an animal.

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.

This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.